Stocks & Investing
Stocks and Investing
Stocks and Investing
Fri, October 25, 2019
[ Fri, Oct 25th 2019
] - WOPRAI
[ Fri, Oct 25th 2019
] - WOPRAI
[ Fri, Oct 25th 2019
] - WOPRAI
[ Fri, Oct 25th 2019
] - WOPRAI
[ Fri, Oct 25th 2019
] - WOPRAI
[ Fri, Oct 25th 2019
] - WOPRAI
[ Fri, Oct 25th 2019
] - WOPRAI
[ Fri, Oct 25th 2019
] - WOPRAI
[ Fri, Oct 25th 2019
] - WOPRAI
[ Fri, Oct 25th 2019
] - WOPRAI
[ Fri, Oct 25th 2019
] - WOPRAI
Thu, October 24, 2019
[ Thu, Oct 24th 2019
] - WOPRAI
[ Thu, Oct 24th 2019
] - WOPRAI
[ Thu, Oct 24th 2019
] - WOPRAI
[ Thu, Oct 24th 2019
] - WOPRAI
[ Thu, Oct 24th 2019
] - WOPRAI
[ Thu, Oct 24th 2019
] - WOPRAI
[ Thu, Oct 24th 2019
] - WOPRAI
[ Thu, Oct 24th 2019
] - WOPRAI
[ Thu, Oct 24th 2019
] - WOPRAI
[ Thu, Oct 24th 2019
] - WOPRAI
[ Thu, Oct 24th 2019
] - WOPRAI
[ Thu, Oct 24th 2019
] - WOPRAI
[ Thu, Oct 24th 2019
] - WOPRAI
[ Thu, Oct 24th 2019
] - WOPRAI
[ Thu, Oct 24th 2019
] - WOPRAI
[ Thu, Oct 24th 2019
] - WOPRAI
[ Thu, Oct 24th 2019
] - WOPRAI
[ Thu, Oct 24th 2019
] - WOPRAI
Joel Beatty Downgraded (ARWR) to Hold and Held Target at $39 on, Oct 24th, 2019
Joel Beatty of Baird, Downgraded "Arrowhead Pharmaceuticals, Inc." (ARWR) to Hold and Held Target at $39 on, Oct 24th, 2019.
Joel has made no other calls on ARWR in the last 4 months.
There are 3 other peers that have a rating on ARWR. Out of the 3 peers that are also analyzing ARWR, 1 agrees with Joel's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Elemer Piros of "Cantor Fitzgerald" Downgraded from Buy to Hold on, Friday, June 28th, 2019
These are the ratings of the 2 analyists that currently disagree with Joel
- Keay Nakae of "Chardan Capital" Maintained at Strong Buy with Increased Target to $45 on, Tuesday, October 22nd, 2019
- Madhu Kumar of "B. Riley Securities" Maintained at Strong Buy with Increased Target to $46 on, Monday, August 19th, 2019
